FDA signs off on CF102 Phase 2 protocol

|By:, SA News Editor

The U.S. Regulator agrees with Can-Fite BioPharma's (CANF) Phase 2 protocol for the Orphan Drug-designated CF102 for the treatment of advanced liver cancer. The 78-patient trial will evaluate the safety and efficacy of CF102 as a second-line treatment for advanced hepatocellular carcinoma (HCC) with Child-Pugh Class B cirrhosis in patients who have failed sorafenib.

In a completed Phase 1/2 trial, CF102 demonstrated an excellent safety profile, lack of hepatotoxicity, prolonged survival time compared to placebo, regression of skin tumor metastases and a stabilization of the disease in 22% of patients.